Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination

Comment on: ‘Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination’ by Gambichler

“…6,7 Of interest, the authors reported that clinical epidemiology of COVID-19 vaccination related PRP seems to be different from classical PRP. 5 Indeed, even if classical PRP has not gender preference, a male preference has been reported with COVID-19 vaccination related PRP (70% of cases). 5 In our opinion, the limited number of cases do not allow to exclude a casual coincidence of gender predominance.…”

“…5 Indeed, even if classical PRP has not gender preference, a male preference has been reported with COVID-19 vaccination related PRP (70% of cases). 5 In our opinion, the limited number of cases do not allow to exclude a casual coincidence of gender predominance. On the contrary, most of the patients who developed PRP following COVID-19 vaccination is around the sixties matching the age of onset of the classical PRP.…”

“…[2][3][4] In this context, we have read with great interest the article recently published by Gambichler entitled 'Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination' evaluating clinical features of the previously published pityriasis rubra pilaris (PRP) cases, and we wanted to add some observations. 5 Until now, 20 cases of PRP have been described, mainly about 10 days after the first dose of vaccination. 5 According with Gambichler, the clinical presentation and the patients' history, as well as the temporal relationship in most cases, suggest a causal relationship between COVID-19 vaccine and PRP development.…”

“…5 According with Gambichler, the clinical presentation and the patients' history, as well as the temporal relationship in most cases, suggest a causal relationship between COVID-19 vaccine and PRP development. 5 In addition, we wanted to highlight that PRP is a rare disease with an unknown pathogenesis. 6 Thus, the pathogenetic mechanism underlying PRP development and COVID-19 vaccination is not clear.…”

“…5 Until now, 20 cases of PRP have been described, mainly about 10 days after the first dose of vaccination. 5 According with Gambichler, the clinical presentation and the patients' history, as well as the temporal relationship in most cases, suggest a causal relationship between COVID-19 vaccine and PRP development. 5 In addition, we wanted to highlight that PRP is a rare disease with an unknown pathogenesis.…”